In the BioHarmony Drug Report Database
Fremanezumab-vfrm
Ajovy (fremanezumab) is an antibody pharmaceutical. Fremanezumab was first approved as Ajovy on 2018-09-14. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1.
Trade Name
|
Ajovy |
|---|---|
Common Name
|
fremanezumab |
ChEMBL ID
|
CHEMBL4297756 |
Indication
|
migraine disorders |
Drug Class
|
Monoclonal antibodies: humanized, neural indications |
Image (chem structure or protein)
